Kazuteru Ohashi - Concepedia

Author

Kazuteru Ohashi

Also Known As

K Ohashi, K. Ohashi, K., Ohashi, KAZUTERU OHASHI, Kayo Egoshi Ohashi, Kazuteru OHASHI, Kazuteru Ohashi, Ohashi, Kazuteru

237

Publications

3.6K

Citations

H-Index

110

Concepts

All Affiliations

Tokyo Metropolitan Komagome Hospital Toranomon Hospital Keio University Nippon Medical School The University of Tokyo

About

Kazuteru Ohashi is an author at Tokyo Metropolitan Komagome Hospital specializing in medicine, hematology, and transplantation.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	21	43	1.6K
2	Health Sciences	12	13	633
3	Natural Sciences	4	4	189
4	Allergy	1	1	33
5	Biochemistry	1	1	94

Kazuteru Ohashi

Publications

3.2K

Citations

H-Index

Page 1

	Year	Citations
Fecal microbiota transplantation for patients with steroid-resistant acute graft-versus-host disease of the gut Kazuhiko Kakihana, Yuki Fujioka, Wataru Suda, Blood	2016	352
Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial Jun Imagawa, Hideo Tanaka, Masaya Okada, The Lancet Haematology Hematological MalignancyMedicineChronic Myeloid LeukaemiaHematologyClinical Trials	2015	297
Bone marrow-derived mesenchymal stem cells (JR-031) for steroid-refractory grade III or IV acute graft-versus-host disease: a phase II/III study Kazuo Muroi, Koichi Miyamura, Masaya Okada, International Journal of Hematology Regenerative MedicineCell TherapyMarrow TransplantationMedicineSteroid-refractory Grade Iii	2015	156
The Japanese multicenter open randomized trial of ursodeoxycholic acid prophylaxis for hepatic veno-occlusive disease after stem cell transplantation Kazuteru Ohashi, Juichi Tanabe, Reiko Watanabe, American Journal of Hematology	2000	150
Prognostic impact of low allelic ratio FLT3-ITD and NPM1 mutation in acute myeloid leukemia Masahiro Sakaguchi, Hiroki Yamaguchi, Yuho Najima, Blood Advances	2018	128
Final 3-year Results of the Dasatinib Discontinuation Trial in Patients With Chronic Myeloid Leukemia Who Received Dasatinib as a Second-line Treatment Masaya Okada, Jun Imagawa, Hideo Tanaka, Clinical Lymphoma Myeloma & Leukemia	2018	116
Prognostic impact of <i>CEBPA</i> bZIP domain mutation in acute myeloid leukemia Satoshi Wakita, Masahiro Sakaguchi, Iekuni Oh, Blood Advances Mixed-phenotype Acute LeukemiaPathologyFavorable PrognosisTumor BiologyMyeloid Neoplasia	2021	116
Chronic kidney disease in long-term survivors of myeloablative allogeneic haematopoietic cell transplantation: prevalence and risk factors Masahiko Ando, Kazuteru Ohashi, Hideki Akiyama, Nephrology Dialysis Transplantation	2009	97
Primary structure of human thromboxane synthase determined from the cDNA sequence. Kazuteru Ohashi, Ke Ruan, Richard J. Kulmacz, Journal of Biological Chemistry Human Thromboxane SynthaseProtein ExpressionCellular EnzymologyBiochemistryEc 5.3.99.5	1992	94
Unrelated allogeneic bone marrow-derived mesenchymal stem cells for steroid-refractory acute graft-versus-host disease: a phase I/II study Kazuo Muroi, Koichi Miyamura, Kazuteru Ohashi, International Journal of Hematology Regenerative MedicineCell TherapyTransplantationMarrow TransplantationPhase I/ii Study	2013	88

Page 1